How to Develop a National Formulary Based on the WHO Model Formulary - A Practical Guide
(2004; 45 pages) View the PDF document
Table of Contents
View the documentAbbreviations
Open this folder and view contents1 INTRODUCTION
Open this folder and view contents2 OVERVIEW OF THE NATIONAL FORMULARY PROCESS
Open this folder and view contents3 DEVELOPING THE PRELIMINARY INFORMATION SECTION
Close this folder4 DEVELOPMENT OF THERAPEUTIC INFORMATION AND MONOGRAPHS USING THE WHO MODEL FORMULARY
View the documentAdapting the therapeutic classification system of the WHO model formulary
View the documentOptions for adapting information from the WHO model formulary in the national formulary
Open this folder and view contentsAddition of locally important, specific information to the WHO model formulary text
View the documentWriting new material for the national formulary
View the documentLanguage, style and presentation
View the documentTechnical copy-editing
Open this folder and view contents5 ADDITIONAL SOURCES OF INFORMATION
Open this folder and view contents6 DEVELOPING SPECIFIC INFORMATION SECTIONS
Open this folder and view contents7 PRODUCTION, DISTRIBUTION AND IMPLEMENTATION
Open this folder and view contents8 EVALUATION
Open this folder and view contents9 REVIEW AND UPDATE
View the documentREFERENCES
 

4 DEVELOPMENT OF THERAPEUTIC INFORMATION AND MONOGRAPHS USING THE WHO MODEL FORMULARY

Guidance in this section mainly applies to the initial development of the NF; those who wish to use the WMF for reviews and updates of their existing NF should consult Chapter 9.

The scope and depth of drug information included in the NF should be appropriate for its intended audience. The WMF can be extensively utilized for the presentation of basic and supplementary information (see Box 4.1) on each drug and therapeutic class. However, there are likely to be cases when new information has to be added. Before new information is inserted, a comprehensive review of available and appropriate drug and therapeutic information should be conducted (more details are given in Chapter 5).

The editorial team will need to draft new text, or suitably qualified professionals can be asked to produce these drafts. To achieve uniform standards of writing and reviewing, and to maintain quality of additional information it is useful to introduce standard requirements for style, content, structure and format; standard operating procedures are useful especially when several people are involved in the writing of the additional material for the NF. For example, the British National Formulary editorial group apply more than 30 written standard operating procedures to direct the different information construction, review and editorial tasks needed for the repeated review process. The use of such quality assurance tools can help to maintain high standards and will also serve as a guide during future revisions of the NF.

Box 4.1. Information to be presented for individual drugs in a formulary

Basic information

Supplementary information

Generic name √

Common brand name(s)

Dosage form and strength √

Price

Main indication √

Level of use or distribution code

Pharmacology/pharmacokinetics √

Prescription category

Contraindications √

Patient information √

Precautions √

Labelling information

Dosage schedule √

Storage instructions and stability

Adverse effects √

Essential drug list number

Drug and food interactions √

Main supplier catalogue number

Instructions, warnings √

Procurement priority code (VEN)
Re-imbursement scheme code

 

√, present in the WMF
VEN, Vital, Essential, Necessary
WMF, WHO model formulary.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 7, 2014